SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Colman Peter G) "

Sökning: WFRF:(Colman Peter G)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Murray, Alison E., et al. (författare)
  • Roadmap for naming uncultivated Archaea and Bacteria
  • 2020
  • Ingår i: Nature Microbiology. - : NATURE PUBLISHING GROUP. - 2058-5276. ; 5:8, s. 987-994
  • Tidskriftsartikel (refereegranskat)abstract
    • The assembly of single-amplified genomes (SAGs) and metagenome-assembled genomes (MAGs) has led to a surge in genome-based discoveries of members affiliated with Archaea and Bacteria, bringing with it a need to develop guidelines for nomenclature of uncultivated microorganisms. The International Code of Nomenclature of Prokaryotes (ICNP) only recognizes cultures as 'type material', thereby preventing the naming of uncultivated organisms. In this Consensus Statement, we propose two potential paths to solve this nomenclatural conundrum. One option is the adoption of previously proposed modifications to the ICNP to recognize DNA sequences as acceptable type material; the other option creates a nomenclatural code for uncultivated Archaea and Bacteria that could eventually be merged with the ICNP in the future. Regardless of the path taken, we believe that action is needed now within the scientific community to develop consistent rules for nomenclature of uncultivated taxa in order to provide clarity and stability, and to effectively communicate microbial diversity. In this Consensus Statement, the authors discuss the issue of naming uncultivated prokaryotic microorganisms, which currently do not have a formal nomenclature system due to a lack of type material or cultured representatives, and propose two recommendations including the recognition of DNA sequences as type material.
  •  
2.
  • Bediaga, Naiara G, et al. (författare)
  • Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample
  • 2021
  • Ingår i: Diabetologia. - : Springer Science and Business Media LLC. - 1432-0428 .- 0012-186X. ; 64:11, s. 2432-2444
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS/HYPOTHESIS: Accurate prediction of disease progression in individuals with pre-symptomatic type 1 diabetes has potential to prevent ketoacidosis and accelerate development of disease-modifying therapies. Current tools for predicting risk require multiple blood samples taken during an OGTT. Our aim was to develop and validate a simpler tool based on a single blood draw.METHODS: Models to predict disease progression using a single OGTT time point (0, 30, 60, 90 or 120 min) were developed using TrialNet data collected from relatives with type 1 diabetes and validated in independent populations at high genetic risk of type 1 diabetes (TrialNet, Diabetes Prevention Trial-Type 1, The Environmental Determinants of Diabetes in the Young [1]) and in a general population of Bavarian children who participated in Fr1da.RESULTS: Cox proportional hazards models combining plasma glucose, C-peptide, sex, age, BMI, HbA1c and insulinoma antigen-2 autoantibody status predicted disease progression in all populations. In TrialNet, the AUC for receiver operating characteristic curves for models named M60, M90 and M120, based on sampling at 60, 90 and 120 min, was 0.760, 0.761 and 0.745, respectively. These were not significantly different from the AUC of 0.760 for the gold standard Diabetes Prevention Trial Risk Score, which requires five OGTT blood samples. In TEDDY, where only 120 min blood sampling had been performed, the M120 AUC was 0.865. In Fr1da, the M120 AUC of 0.742 was significantly greater than the M60 AUC of 0.615.CONCLUSIONS/INTERPRETATION: Prediction models based on a single OGTT blood draw accurately predict disease progression from stage 1 or 2 to stage 3 type 1 diabetes. The operational simplicity of M120, its validity across different at-risk populations and the requirement for 120 min sampling to stage type 1 diabetes suggest M120 could be readily applied to decrease the cost and complexity of risk stratification.
  •  
3.
  • Callaghan, Terry V., et al. (författare)
  • Changing snow cover and its impacts
  • 2011
  • Ingår i: Snow, Water, Ice and Permafrost in the Arctic (SWIPA). - Oslo : Arctic Monitoring and Assessment Programme. - 9788279710714 ; , s. 4:1-4:58
  • Bokkapitel (refereegranskat)
  •  
4.
  • So, Michelle, et al. (författare)
  • Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies : Beyond a Simple Count
  • 2021
  • Ingår i: Endocrine Reviews. - : The Endocrine Society. - 0163-769X .- 1945-7189. ; 42:5, s. 584-604
  • Forskningsöversikt (refereegranskat)abstract
    • Islet autoantibodies are key markers for the diagnosis of type 1 diabetes. Since their discovery, they have also been recognized for their potential to identify at-risk individuals prior to symptoms. To date, risk prediction using autoantibodies has been based on autoantibody number; it has been robustly shown that nearly all multiple-autoantibody-positive individuals will progress to clinical disease. However, longitudinal studies have demonstrated that the rate of progression among multiple-autoantibody-positive individuals is highly heterogenous. Accurate prediction of the most rapidly progressing individuals is crucial for efficient and informative clinical trials and for identification of candidates most likely to benefit from disease modification. This is increasingly relevant with the recent success in delaying clinical disease in presymptomatic subjects using immunotherapy, and as the field moves toward population-based screening. There have been many studies investigating islet autoantibody characteristics for their predictive potential, beyond a simple categorical count. Predictive features that have emerged include molecular specifics, such as epitope targets and affinity; longitudinal patterns, such as changes in titer and autoantibody reversion; and sequence-dependent risk profiles specific to the autoantibody and the subject's age. These insights are the outworking of decades of prospective cohort studies and international assay standardization efforts and will contribute to the granularity needed for more sensitive and specific preclinical staging. The aim of this review is to identify the dynamic and nuanced manifestations of autoantibodies in type 1 diabetes, and to highlight how these autoantibody features have the potential to improve study design of trials aiming to predict and prevent disease.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4
Typ av publikation
tidskriftsartikel (2)
forskningsöversikt (1)
bokkapitel (1)
Typ av innehåll
refereegranskat (4)
Författare/redaktör
Colman, Peter G (2)
Bulygina, Olga N. (1)
Christensen, Torben ... (1)
Forbes, Bruce C. (1)
Vandamme, Peter (1)
Robinson, David A. (1)
visa fler...
Lane, Christopher E. (1)
Rautio, Arja (1)
Johansson, Margareta (1)
Sköld, Peter, 1961- (1)
Shindell, Drew (1)
Ettema, Thijs J. G. (1)
Pedros-Alio, Carlos (1)
Lundgren, Markus (1)
Ziegler, Anette-Gabr ... (1)
Warren, Stephen (1)
Lernmark, Ake (1)
Razuvaev, Vyacheslav ... (1)
Haller, Michael J. (1)
Phoenix, Gareth K. (1)
Wagner, Michael (1)
Baker, Brett J. (1)
Probst, Alexander J. (1)
DiMeglio, Linda A. (1)
Evans-Molina, Carmel ... (1)
Gitelman, Stephen E. (1)
Greenbaum, Carla J. (1)
Gottlieb, Peter A. (1)
Herold, Kevan C. (1)
Wherrett, Diane K. (1)
Wood, Eric F. (1)
Bediaga, Naiara G (1)
Li-Wai-Suen, Connie ... (1)
Hippich, Markus (1)
Harrison, Leonard C (1)
Wentworth, John M (1)
Armengaud, Jean (1)
Steck, Andrea K. (1)
Whitman, William B. (1)
Speake, Cate (1)
Brown, Ross D. (1)
Essery, Richard L. H ... (1)
Sokratov, Sergey A. (1)
Callaghan, Terry V. (1)
Hentschel, Ute (1)
Konstantinidis, Kons ... (1)
Eisen, Jonathan A. (1)
Parks, Donovan H. (1)
Hugenholtz, Philip (1)
Tiedje, James M. (1)
visa färre...
Lärosäte
Lunds universitet (2)
Umeå universitet (1)
Uppsala universitet (1)
Språk
Engelska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (3)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy